(formerly ModeRNA) is an American biotech company focused on drug discovery and drug and vaccine development based exclusively on messenger RNA (mRNA). After a decade of work and on financially shaky ground due to its inability to develop drugs safe enough for human testing, the company hit jackpot in April 2020, when Trump appointed Moderna board member Moncef Slaoui to Operation Warp Speed, the plan to vaccinate the entire American population by 2021. In November 2020, the company launched its Covid-19 vaccine, its first commercially allowed product.
In 2010, ModeRNA Therapeutics was formed to commercialize the research of stem cell biologist Derrick Rossi, who developed a method for modifying mRNA, transfecting it into human cells, then dedifferentiating it into stem cells that could then be further dedifferentiated into desired target cell types. Highly secretive, over its lifespan the company has been noticeably reluctant to release data about its product developments.[1]
Moderna has received considerable U.S. government/military funding[2] ($438 million) from the Biomedical Advanced Research and Development Authority (BARDA), a division of HHS overseen by HHS’ Assistant Secretary for Preparedness and Response (ASPR) Robert Kadlec. Moderna has also stated that it is directly collaborating with the U.S. government to bring its vaccine candidate to market.[3]
Moderna’s regulatory success has also been result of backing that it received in January 2020 from the Coalition for Epidemic Preparedness Innovations (CEPI), which was founded in 2017 by the governments of Norway and India along with the World Economic Forum (WEF) and the Bill and Melinda Gates Foundation.
Moderna’s Covid-19 vaccine has also received additional millions from long-time Moderna backer Bill Gates. The Bill & Melinda Gates Foundation is the only foundation listed as a “strategic collaborator” on the Moderna website. In April 2020, Gates authored an article where he described Moderna’s mRNA vaccine for Covid-19 as the “most exciting” and discussed it at length, writing “It’s a bit like building your computer system and your first piece of software at the same time.”[4]
The company has worked with BARDA for an improved Zika virus vaccine candidate, and DARPA for advancing mRNA therapies and vaccines for biodefense[5].
In December 2018, Moderna became the largest biotech initial public offering (IPO) in history, raising $600 million for 8% of its shares, implying an overall valuation of $7.5 billion[6]. Fitting for its military/intelligence ties, the company has a reputation for secrecy and little of its work has ever been published, and none peer-reviewed or scientifically validated[7].
World Economic Forum
Moderna’s CEO Stéphane Bancel was selected a Young Global Leader by the World Economic Forum in 2009. This community, where most Young Leaders participate in yearly gatherings for 5 years and where ambitious Young Leaders get assessed and scouted by billionaires like Bill Gates, presumably was one of the reasons why he got the top job.
Moderna first teamed up with the WEF just a few years after its founding back in 2013, when it was named to the Forum’s community of Global Growth Companies (GGC). That year, Moderna was one of just three North American health companies to receive the honor and was additionally recognized by the Forum as “an industry leader in innovative mRNA therapeutics.”[8] Such carefully selected companies are given opportunities by the Forum “to shape global, regional and industry agendas and engage in meaningful exchanges about ways to continue on a sustainable and responsible path of growth.” Essentially, the roster of such companies constitutes a consortium of corporations that are promoted and guided by the Forum because of their commitment to “improving the state of the world,” that is, their commitment to supporting the Forum’s long-term agendas for the global economy and for global governance.[9]
In 2019 Moderna’s Bancel attended the World Economic Forum’s 2019 annual meeting[10] alongside Johnson & Johnson executive Paul Stoffels and other pharmaceutical and biotech leaders in order to “rub elbows with world leaders and one-percenters—and talk about the future of healthcare.” Other health-care figures in attendance included head of the World Health Organization, Tedros Adhanom Ghebreyesus, and “global health philanthropist” Bill Gates, whose foundation entered into “a global health project framework”[11] with Moderna in 2016 to “advance mRNA-based development projects for various infectious diseases.”.[9]
In 2016, Peter Kolchinsky, whose RA Capital Management owns a stake in the company stated, remarkably presciently[12]:
“We think that when the world does get to see Moderna, they’re going to see something far larger in its scope than anybody’s seen before.”
Never proved safe enough to test in humans
In 2016 Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future at the annual J.P. Morgan Healthcare Conference. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016. It was to be the first therapy using a new mRNA technology that Bancel promised would yield dozens of drugs in the coming decade. But the Crigler-Najjar treatment has been indefinitely delayed, as it never proved safe enough to test in humans.[1]
As the health magazine STAT explained: “In order to protect mRNA molecules from the body’s natural defenses, drug developers must wrap them in a protective casing. For Moderna, that meant putting its Crigler-Najjar therapy in nanoparticles made of lipids. And for its chemists, those nanoparticles created a daunting challenge: Dose too little, and you don’t get enough enzyme to affect the disease; dose too much, and the drug is too toxic for patients.”[1]
Covid-19 Vaccine
- Full article: Moderna COVID-19 vaccine
Moderna states on its website, under the heading The ‘Software of Life’:
When we have a concept for a new mRNA medicine and begin research, fundamental components are already in place.
Generally, the only thing that changes from one potential mRNA medicine to another is the coding region – the actual genetic code that instructs ribosomes to make protein. Utilizing these instruction sets gives our investigational mRNA medicines a software-like quality. We also have the ability to combine different mRNA sequences encoding for different proteins in a single mRNA investigational medicine.
We are leveraging the flexibility afforded by our platform and the fundamental role mRNA plays in protein synthesis to pursue mRNA medicines for a broad spectrum of diseases.[13]
Under a rule put in place by the Securities and Exchange Commission in 2000 to allow company employees to sell shares without facing insider-trading charges, several Moderna executives (just like in fellow Big Pharma Pfizer) have – legally – sold shares worth more than $100 million during the summer and autumn 2020.[14] Since January, CEO Stéphane Bancel has sold roughly $40 million worth of Moderna stock held by himself or associated investment funds; Chief Medical Officer Tal Zaks, the medical face outwards of the US company and of the key figures in the development of its Covid-19 vaccine, has sold around $60 million; and President Stephen Hoge has sold more than $10 million.
Commenting on the stock sales, Daniel Taylor, an associate professor of accounting at the Wharton School stated:
“On a scale of one to 10, one being less concerned and 10 being the most concerned, this is an 11.”[15]
In July 2021, Tal Zak left the company and sold most of his remaining shares. Per August 23, he only had 1,5 million dollars in shares left. Also Bancel keeps selling down.[16]
Tax avoidance
The US-based company passed the profits it made on sales of its coronavirus vaccine in Europe to a shell company in Switzerland to avoid paying tax. By June 2021, orders from the EU brought in €10.3 billion, allowing the company to issue an income forecast for the year of €19 billion and a profit of €4.4 billion. But the countries of the EU will see none of it. Swiss corporation tax is a maximum of 13%, but the company can easily manage to reduce that to 7.8%. And having done so, its tax obligations are fulfilled.[17]
The company does the same in the United States. It is based in the state of Massachusetts, but its patents are registered in Delaware (the home state of US president Joe Biden), where royalties – including the income from vaccines – are not taxed at all.[17]
People
Since 2011, Moderna has been led by CEO Stéphane Bancel, a French businessman who is not a scientist and comes from a pharma sales and operations background. A first-time biotech CEO, Bancel, has “an unwavering belief that Moderna’s science will work — and that employees who don’t “live the mission” have no place in the company.”[12]
An 2016 investigation by the health magazine STAT investigation found that Bancel had “driven away top talent from Moderna with a culture of recrimination and a caustic work environment, including on-the-spot firings for failed experiments.” At least a dozen highly placed executives have quit since 2012, including heads of finance, technology, manufacturing, and science. In 2016, respected leaders of Moderna’s cancer and rare disease programs both resigned, even though the company’s remarkable fundraising had put ample resources at their disposal.[1]
After Noubar Afeyan and Robert Langer, Bancel is the largest individual shareholder in the company.
Stephen Hoge is President and a former McKinsey & Company management consultant who joined in 2012; he is the fourth-largest individual shareholder in the company.
Lorence Kim is CFO and a former Goldman Sachs biotech investment banking managing director who joined in 2014; he is the fifth-largest individual shareholder in the company.
Since 2011, the Chairman of Moderna has been the CEO of Flagship Pioneering, businessman Noubar Afeyan. Afeyan holds his interest in Moderna through various Flagship Pioneering vehicles, however, at the 2018 IPO, documents filed stated that Afeyan owned 19.5% of the company, while Flagship owned 18%, thus giving Afeyan control over 37.5% of the company[18].
Dr. Tal Zaks, an Israeli citizen[19] who began his career at GlaxoSmithKline, oversaw “preclinical development, clinical development and regulatory affairs” for Moderna and all of its subsidiaries until he left the company in July 2021.
Chancellor Rishi Sunak
On 1 July 2022, Oliver tweeted:
Rishi Sunak is being asked to approve tax-payer funded investments in vaccine maker Moderna.
Major shareholder of Moderna is hedge fund Theleme, co-founded in 2009 by Sunak, who no doubt retained lots of shares.[20]
Sunak won’t comment whether this is #ToryCorruption via Private Eye.[21]
Moderna is Spying on You
In a significant legal development, a vaccine victim who suffered severe nerve damage after receiving a COVID-19 shot, along with four other individuals with confirmed or suspected vaccine injuries, filed a lawsuit against Joe Biden and his administration back in May, Epoch Times reported. The lawsuit was filed in southern Texas. Aside from Biden, defendants include his top adviser Rob Flaherty, White House communications secretary Karine Jean-Pierre, the Department of Homeland Security, the Centers for Disease Control and Prevention, and Surgeon General Vivek Murthy, and others.
The plaintiffs alleged that the Biden regime violated their rights to free speech and peaceful assembly by pressuring big tech to crack down on individuals sharing their adverse reactions following COVID-19 vaccinations. They plaintiffs claimed that the defendants have resorted to threats, pressure, inducement, and coercion to suppress their voices.
In August last year, The Gateway Pundit joined the Missouri-Louisiana lawsuit against the Biden administration in their efforts to censor, block, remove, and shadow-ban opinions and facts that ran up against their opinions and alleged ‘truths’.
The Missouri-Louisiana lawsuit is likely heading to the Supreme Court.
We have known for years now that Big Pharma was working with the government to censor opponents to their vaccine agenda.
Now, a new report by Unherd.com found that Moderna has been spying on Americans and shutting down discourse with the help of Big Tech and the US government.
Moderna is monitoring a massive range of mainstream media and independent media to shut down anything that might undermine vaccine policy and Big Pharma propaganda.
Moderna is even using Talkwalker artificial intelligence to monitor vaccine-related conversations across 150 million websites in nearly 200 countries.
Moderna is spying on you.
Unherd.com reported:
The most important thing for Moderna is that people keep having their jabs. Smart ads are part of that. But more important is to push back aggressively against any prevailing anti-vax narrative and engage where possible in any discussions around vaccine policy. That’s where the Moderna disinformation department comes in.
Behind the scenes, the marketing arm of the company has been working with former law enforcement officials and public health officials to monitor and influence vaccine policy. Key to this is a drug industry-funded NGO called Public Good Projects. According to documents we have seen, PGP works closely with social media platforms, government agencies and news websites to confront the “root cause of vaccine hesitancy” by rapidly identifying and “shutting down misinformation”. A network of 45,000 healthcare professionals are given talking points “and advice on how to respond when vaccine misinformation goes mainstream”, according to an email from Moderna.
Moderna’s disinformation arm is perpetuating the public discourse wars that have been raging since early in the pandemic, aimed at shutting down anything that might undermine Covid-19-related policies, including lockdowns and efforts to encourage mass vaccinations. These documents provide a new window into the process that has roiled speech debates over the last three years.
With PGP, Moderna is monitoring a huge range of mainstream outlets, as well as unconventional ones, such as the Steam online gaming community and Medium. Meanwhile, Moderna also retains Talkwalker which uses its “Blue Silk” artificial intelligence to monitor vaccine-related conversations across 150 million websites in nearly 200 countries. Discussions around “competitor” issues, including discussions of Pfizer are flagged as well as vaccine hesitancy.
Their monitoring team includes Moderna’s global intelligence division, which is run by Nikki Rutman, who spent nearly 20 years as an analyst with the Federal Bureau of Investigation. Rutman was working from the FBI’s Boston office during the COVID-19 effort known as “Operation Warp Speed”, which involved the FBI conducting weekly cybersecurity meetings with the Boston headquartered Moderna. She is among many former law enforcement agents now with the vaccine maker. The involvement of former law enforcement reflects a wider trend in the misinformation-space, as the Department of Homeland Security and FBI have increasingly leaned on social media platforms to shape content decisions as a national security issue.
Further reading
Whitney Webb wrote a long analysis about the dubious science and business practices of Moderna:
Source: Wikispooks
Chronological History of Events Related to Moderna
The Vaccine Death Report: Evidence of millions of deaths and serious adverse events from Covid Vax
“Undeclared Components of Covid-19 Vaccines” Symposium in Germany
The German Club of Clear Words Report: Exposes the network of individuals and organizations responsible for the COVID scam
Japan Recalls 1.63 Million Doses Of Moderna Covid Vaccine Due To Foreign Material Contamination
Moderna Trial Documents: Lab Rat Offspring Got Rib Malformations After COVID Vaccination
CDC Study Claims Unvaxxed 2X+ More Likely than Vaxxed to be Reinfected with COVID-19
Doctor Breaks Gag Order: Speaks Publicly On Moderna Covid-19 Vaccine Harm in First Nations Community
Lawsuit Exposes COVID Jabs As Unsafe Transhumanist Gene Therapies
FDA Says 2 Participants In Pfizer COVID Vaccine Trial Have Died
